Gallbladder Diseases
Conditions
Brief summary
The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in male patients who are reversed with sugammadex or neostigmine.
Detailed description
Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.
Interventions
Sugammadex of 3 mg/kg is injected.
Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
Sponsors
Ajou University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
MALE
Age
65 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Laparoscopic cholecystectomy under general anesthesia
Exclusion criteria
* BMI \> 30 kg/m2, respiratory infection, uncontrolled hypertension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| optimal Ce of remifentanil | from the ene of surgery until endotracheal extubation | Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia |
Countries
South Korea
Outcome results
None listed